Highlights of Ending Age-Related Diseases 2020
Key points from 20 presentations from world-leading researchers
Matthew O’Connor
Co-Chief Executive Officer and Co-founder of Cyclarity Therapeutics (former Underdog Pharmaceuticals)
Dr. O’Connor was awarded his Master’s degree in neuroscience from Northwestern Medical in 1999 and his PhD in Biochemistry from Baylor College of Medicine in 2005. His postdoctoral research includes work at UC Berkeley on muscle stem cells and aging. He is the author of 10 published manuscripts and lead inventor on the cyclodextrin patents. He is the outgoing VP of Research at SENS Research Foundation.
Visit website: https://underdogpharma.com/team/
See also: 
Cyclarity Therapeutics
- Company developing simple and direct interventions targeting toxic forms of cholesterol for age-related diseases.
Details last updated 11-Mar-2020
Matthew O’Connor is also referenced in the following:
LessDeath
Research company that helps people join the Longevity Biotechnology industry through education and more
Longevity Hackers
Feature length documentary about longevity and radical life extension with due to be released in 2023
Longevity Summit Dublin 2022
18-Sep-2022 to 20-Sep-2022
Event gathering Global Longevity and Rejuvenation community in Dublin with many longevity movement superstars as speakers
Matthew O’Connor Blog Posts
10-Sep-2020
Matthew O’Connor News
Lifespan.io speaks to Cyclarity’s CEO for an update on its novel atherosclerosis treatment
Lifespan.io (LEAF) - 19-Feb-2024
The company is developing a drug called UDP-003 to treat the disease
Read more...'Innovation Passport' awarded for Underdog's novel compound intended for treating heart diseases
Longevity Technology - 09-Sep-2021
Safe and potential compound shows disease-modifying effect by removing toxic cholesterol from blood
Read more...
